Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans
Open Access
- 30 July 2002
- journal article
- case report
- Published by Wiley in International Journal of Cancer
- Vol. 100 (6), 623-626
- https://doi.org/10.1002/ijc.10535
Abstract
Dermatofibrosarcoma protuberans (DFSP) is a rare superficial sarcoma usually affecting the trunk, with significant risk of local recurrence. It is characterized by the presence of ring chromosomes or chromosomal translocations fusing the promoter of the collagen gene COL1A1 to the platelet‐derived growth factor β‐chain gene PDGFB, increasing the production of PDGF locally and promoting autocrine or paracrine tumor growth. Fewer than 5% of patients with DFSP develop metastatic sarcoma, with a poor subsequent prognosis. Imatinib (STI‐571) was developed as an inhibitor of the PDGF receptor tyrosine kinase and has proven clinical activity against chronic myelogenous leukemia (expressing bcr‐abl) and gastrointestinal stromal tumors (expressing c‐kit). We describe 2 patients with metastatic and unresectable metastases from DFSP treated with imatinib. After confirmation of negative CD117 status of 2 sarcomas arising from DFSP, patients were given imatinib 400 mg po qd and assessed at regular intervals for their tolerance and response to therapy. One patient had a transient response, then progressed rapidly and died of disease. Another patient showed a partial response to therapy after 2 months, with resolution of superior vena cava syndrome and shrinking of metastatic lung lesions. His response is ongoing after 6 months of therapy. These clinical data confirm findings from models of DFSP and support the use of imatinib in the rare setting of metastatic DFSP. Imatinib may be useful for patients with locally advanced DFSP, when other options for local therapy are limited.Keywords
This publication has 7 references indexed in Scilit:
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.International Journal of Cancer, 2001
- Various regions within the alpha-helical domain of theCOL1A1 gene are fused to the second exon of thePDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomasGenes, Chromosomes and Cancer, 1998
- Supernumerary ring chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma protuberansCancer Genetics and Cytogenetics, 1990